Abstract:
BACKGROUND:In 2008, China introduced live, attenuated hepatitis A vaccine (L-HepA, licensed in 1992) and inactivated hepatitis A vaccine (I-HepA, licensed in 2002) nationwide, and is currently the only country using L-HepA in routine immunization. We assessed seropositivity and its duration following vaccination, safety, and association with hepatitis A incidence and population seroprevalence for I-HepA and L-HepA. METHODS:We obtained seroprevalence data from two nationwide serosurveys (in 1992 and 2014), vaccination status from the 2014 serosurvey, and vaccine safety and disease incidence data from the national surveillance system. We compared long-term HAV seropositivity among vaccine recipients and described safety profiles of both vaccines. We categorized the 31 provinces into those predominately using I-HepA and achieving high coverage (n = 4), those predominately using L-HepA achieving high coverage (n = 4), and those predominately using L-HepA achieving lower coverage (n = 23). We compared population HAV seropositivity, coverage, and disease incidence among the three groups. RESULTS:One year after vaccination, seropositivity from I-HepA was significantly higher than from L-HepA (97.8% vs 90.7%), and seropositivity declined to 73.5% for L-HepA and 75.4% for I-HepA after 10 years - not significantly different by vaccine. The annual incidence of serious AEFI was <0.5/100 000 for both vaccines. Prior to licensure of either HepA vaccine, provinces that would go on to predominantly use I-HepA had lower incidences of hepatitis A and lower seropositivity levels to HAV than provinces that would go on to use L-HepA. By 2014, these differences were significantly diminished. Regardless of vaccine selection, all three province groups had lower immunity to HAV among individuals born during the 10 years prior to nationwide vaccine introduction - individuals who were 10 to 24 years old in 2014. CONCLUSION:Evidence of good immunogenicity, safety, and impact on incidence supports continued use of both I-HepA and L-HepA in the EPI system. These results may be useful for countries considering integrating HepA vaccines into their routine programs.
journal_name
Vaccinejournal_title
Vaccineauthors
Xiaojin S,Rodewald LE,Guomin Z,Hui Z,Ning M,Fuzhen W,Zundong Ydoi
10.1016/j.vaccine.2020.11.019subject
Has Abstractpub_date
2020-12-14 00:00:00pages
8302-8309issue
52eissn
0264-410Xissn
1873-2518pii
S0264-410X(20)31457-2journal_volume
38pub_type
杂志文章相关文献
VACCINE文献大全abstract::In the last quarter of the year 2000, the meningococcal C conjugated vaccine was incorporated into the routine vaccination schedule in Catalonia (at 2, 4 and 6 months). In addition a vaccination campaign was carried out in children <6 years of age, with a coverage of 96.2%. The effectiveness of the vaccination in this...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(02)00590-x
更新日期:2003-01-30 00:00:00
abstract::Intranasal (i.n.) vaccination with two suboptimal doses of 8 microg of deglycosylated chain A ricin (DGCA) stimulated low anti-ricin ELISA IgG and neutralizing antibody responses and the vaccine was only marginally protective against a lethal ricin toxin aerosol challenge. However, in the presence of 4, 2, or 1 microg...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2004.12.034
更新日期:2006-03-15 00:00:00
abstract::Enterobactin (Ent)-mediated high affinity iron acquisition is critically important for Gram-negative bacterial pathogens to survive and infect the host. Recently, we reported an efficient method to prepare novel Ent conjugate vaccines for inducing high level of Ent-specific antibodies, which displayed similar bacterio...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2020.10.040
更新日期:2020-11-17 00:00:00
abstract::The hepatitis B virus (HBV) has infected more than 2000 million persons alive today and 350 million persons are chronically infected carriers of the virus, at high risk of death from active hepatitis, cirrhosis and primary hepatocellular cancer. Each year approximately 1 million people die from the acute and chronic s...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/0264-410x(95)80050-n
更新日期:1995-01-01 00:00:00
abstract::The calculation of p(epitope) values, a sequence-based measure of antigenic distance between strains, was developed for human influenza. The potential to apply the p(epitope) value to equine influenza vaccine strain selection was assessed. There was a negative correlation between p(epitope) value and vaccine efficacy ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2013.06.070
更新日期:2013-12-09 00:00:00
abstract::The candidate vaccine virus NIBRG-14 was derived by reverse genetics and comprises the haemagglutinin (HA) and neuraminidase (NA) genes derived from the clade 1 virus A/Viet Nam/1194/2004 on an A/Puerto Rico/8/34 (PR8) backbone. The HA gene was modified to remove the multibasic cleavage site motif associated with high...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2010.09.006
更新日期:2010-11-23 00:00:00
abstract::In order to establish a firm preventive measure for tick-borne encephalitis (TBE) in Japan, we evaluated the immune response of European vaccine against Japanese TBE virus strain (Oshima 5-10) for man and mouse. Furthermore, the efficacy of pre- and post-exposure protection by a polyclonal rabbit anti-TBE virus serum ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(98)00360-0
更新日期:1999-03-17 00:00:00
abstract::Consumed for centuries, lactic acid bacteria are excellent candidates for the development of safe mucosal delivery vehicles for prophylactic and therapeutic molecules. We have recently reported that the immune response to an effective OspA-expressing L. plantarum vaccine for Lyme disease is modulated by the lipid modi...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2010.07.084
更新日期:2010-09-24 00:00:00
abstract::The immunotherapeutic properties of a new Pythium insidiosum-vaccine formulation (PIV), was evaluated in 18 horses and 6 dogs with proven pythiosis from different enzootic areas in the United States. All injected horses but one responded with a weak (=29 mm, n=3), a mild (30-90 mm, n=7) or a strong (=100 mm, n=7) infl...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(03)00225-1
更新日期:2003-06-20 00:00:00
abstract::Chagas' disease is a major tropical disease for which a cure for chronic phase does not exist yet. Trypanosoma cruzi trans-sialidase (TS) seems to be involved in relevant processes such as infectivity, host survival and, very importantly, disease pathogenesis. In this study, we show that mice vaccinated with an engine...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2008.02.060
更新日期:2008-05-02 00:00:00
abstract::Designation as a Category B biothreat agent has propelled Coxiella burnetii from a relatively obscure, underappreciated, "niche" microorganism on the periphery of bacteriology, to one of possibly great consequence if actually used in acts of bioterrorism. Advances in the study of this microorganism proceeded slowly, p...
journal_title:Vaccine
pub_type: 杂志文章,评审
doi:10.1016/j.vaccine.2007.08.002
更新日期:2007-10-16 00:00:00
abstract::Using HIV-1 envelope protein (Env)-based immunogens that closely mimic the conformation of functional HIV-1 Envs and represent the isolates prevalent in relevant geographical region is considered a rational approach towards developing HIV vaccine. We recently reported that like clade B Env, JRFL, membrane bound Indian...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2018.01.081
更新日期:2018-03-14 00:00:00
abstract::Parainfluenza virus type 1 (PIV1) is a major cause of croup in infants and young children, and a vaccine is needed to prevent the serious disease caused by this virus. In the present study, a live attenuated PIV1 vaccine candidate was generated by modification of the extensively-studied PIV3 cold-passaged (cp) cp45 va...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(99)00227-3
更新日期:1999-10-14 00:00:00
abstract::A safe, effective and accessible preventive vaccine is our best long-term hope for the control of the HIV/AIDS pandemic. The first phase I trial of an HIV vaccine was conducted in the US in 1987. Since then, >30 candidate vaccines have been tested in over 60 phase I/II clinical trials, involving >8000 healthy human vo...
journal_title:Vaccine
pub_type: 杂志文章,评审
doi:10.1016/s0264-410x(02)00062-2
更新日期:2002-05-06 00:00:00
abstract:BACKGROUND:China is the most populous country in the world, with an annual birth cohort of approximately 16 million, requiring an average of 500 million vaccine doses administered annually. In China, over 30 domestic and less than 10 overseas vaccine manufacturers supply over 60 licensed vaccine products, representing ...
journal_title:Vaccine
pub_type: 杂志文章,评审
doi:10.1016/j.vaccine.2012.11.051
更新日期:2013-01-11 00:00:00
abstract::In a Phase 2a trial of the RTS,S/AS vaccine, we described significant association between protection against infection and vaccine-induced CD4 T cells. To determine whether processing of the circumsporozoite protein as a component of the RTS,S particulate antigen yields the same HLA-DR-restricted epitopes as those rec...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2011.09.098
更新日期:2011-11-08 00:00:00
abstract::sLAG-3 (IMP321), a natural high affinity ligand for MHC class II, was tested for safety, tolerability and its ability to increase Th-1-type T cell responses to a commercial trivalent split influenza vaccine (Agrippal) in a phase I single-blinded, randomized, controlled clinical trial. Twenty healthy volunteers were fi...
journal_title:Vaccine
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.vaccine.2007.04.019
更新日期:2007-06-11 00:00:00
abstract::A systematic comparison of the immunostimulatory capacity of TLR 2, 3, 4, 5, 7 and 9 agonists and an agonistic CD40-specific antibody was performed in a single long peptide vaccination model. All adjuvants activated DC in vitro but not all induced a strong functional T-cell response in vivo. Optimal clonal CD8(+) T-ce...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2006.10.049
更新日期:2007-02-09 00:00:00
abstract::Seasonal influenza epidemics represent a substantial public health burden, causing significant morbidity and mortality. Influenza in humans can be caused by influenza type A and type B viruses, and although influenza A is responsible for the majority of seasonal influenza infections, influenza B disease is common in c...
journal_title:Vaccine
pub_type: 杂志文章,评审
doi:10.1016/j.vaccine.2010.08.028
更新日期:2010-09-07 00:00:00
abstract:BACKGROUND:In January 2015, Tajikistan introduced the monovalent rotavirus vaccine into the national immunization program. Our objective was to estimate pre-vaccine burden of rotavirus-associated hospitalizations in children <5 years of age in Tajikistan. METHODS:During January 2013-December 2014, active surveillance ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2017.08.031
更新日期:2018-12-14 00:00:00
abstract::Antibodies specific for Vibrio cholerae lipopolysaccaride (LPS) are common in humans recovering from cholera, and constitute a primary component of the vibriocidal response, a serum complement-mediated bacteriocidal response correlated with protection against cholera. In order to determine whether transcutaneous immun...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2009.06.040
更新日期:2009-08-06 00:00:00
abstract::The emergence of pneumococcal strains resistant to penicillin caused a lot of problems in the therapy of invasive diseases, and added new dimensions to the role of immunisation. In addition to the currently available 23-valent pneumococcal polysaccharide vaccine (PPV) and a new 7-valent conjugate vaccine (PCV) (Prevna...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(03)00518-8
更新日期:2003-12-01 00:00:00
abstract::Infections with the intracellular protozoan parasite Toxoplasma gondii pose a serious public health problem and are of great economic importance worldwide. The parasite rhoptry protein 5 (ROP5) has been implicated as a major virulence factor that reduces the accumulation of immunity-related GTPases (IRG) in parasitoph...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2013.07.058
更新日期:2013-09-23 00:00:00
abstract:BACKGROUND:Following a recommendation by the World Health Organization, Madagascar introduced rotavirus vaccine in 2014. Though national rotavirus vaccine coverage has remained <80%, rotavirus hospitalizations declined by 78%. Gavi, the Vaccine Alliance, has provided financial support for rotavirus vaccine, however the...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2020.09.082
更新日期:2020-11-03 00:00:00
abstract:BACKGROUND:Cervical cancer is one of the most prevalent cancers in women caused by the human papillomavirus (HPV) that leads to a substantial disease burden for health systems. Prevention through vaccination can significantly reduce the prevalence of cervical cancer. The objective of this study is to evaluate the poten...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2019.10.037
更新日期:2020-01-10 00:00:00
abstract::A new rabies vaccine was developed from Vero cells adhered to microcarriers, cultivated in a bioreactor in serum-free medium and infected with the PV/VERO-Paris rabies virus strain. The viral suspensions were concentrated by tangential filtration, purified by chromatography and inactivated with beta-propiolactone. In ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2004.06.014
更新日期:2004-12-09 00:00:00
abstract::First year medical students at an allopathic medical school regional campus were asked to complete a 10-question survey at both the beginning and the conclusion of a required course on immunology, hematology and oncology. The survey was designed to solicit student attitudes about vaccination and the students' level of...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2019.10.094
更新日期:2020-01-22 00:00:00
abstract::In 2013, avian H7N9 influenza viruses were detected infecting people in China resulting in high mortality. Influenza H7 vaccines that provide cross-protection against these new viruses are needed until specific H7N9 vaccines are ready to market. In this study, an available H7N3 cold-adapted, temperature sensitive, liv...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2014.11.008
更新日期:2015-01-01 00:00:00
abstract::Successful emergency vaccination campaigns rely on effective deployment and vaccination plans. This applies to localised outbreaks as well as for pandemics. In the wake of the 2009 H1N1 influenza pandemic, analysis of the global Vaccine Deployment Initiative, through which the World Health Organization (WHO) donated p...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2020.11.047
更新日期:2021-01-08 00:00:00
abstract:BACKGROUND:Vaccinations are an effective choice to stop disease outbreaks, including COVID-19. There is little research on individuals' COVID-19 vaccination decision-making. OBJECTIVE:We aimed to determine individual preferences for COVID-19 vaccinations in China, and to assess the factors influencing vaccination deci...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2020.12.009
更新日期:2021-01-08 00:00:00